TABLE 2

Results of RVP Testing and Clinical Outcomes in Children With Community-Acquired Pneumonia.

RVP NegativeRVP Positive
All VirusesRSVRV/EVhMPV/PIV/IFVAdV/CoV/BV
(n = 75)(n = 127)(n = 32)(n = 35)(n = 32)(n = 13)
Median age, y (IQR)3 (0.3–8)1 (0.3–4)a1 (0.1–2)a3 (0.8–6)2 (0.8–4)1 (0.3–5)
Outcomes
 Median LOS, d (IQR)3 (2–7)4 (2–7)6 (4–11)a3 (2–5)4 (3–9)3 (2–6)
 Respiratory support62 (83.8%)114 (89.8%)31 (96.9%)30 (85.7%)28 (87.5%)12 (92.3%)
 Median duration of respiratory support, d (IQR)2 (1–5)3 (2–5)a4.5 (3–8)b2 (1–4)3 (2–5)2 (2–4)
Intensive care admission41 (55.4%)81 (63.8%)24 (75%)a19 (54.3%)19 (59.4%)9 (69.2%)
Invasive mechanical ventilation13 (17.6%)42 (33.1%)a14 (43.8%)b7 (20%)11 (34.4%)4 (30.8%)
Parenteral antibiotic therapy66 (89.2%)122 (96.1%)30 (93.8%)34 (97.1%)30 (93.8%)13 (100%)
Median duration of parenteral antibiotics, h (IQR)65 (37–121)62 (40–144)72.5 (44–148)53 (36–101)68 (24–169)66 (44–124)
  • Respiratory support is defined as any supplemental oxygen or positive pressure ventilation. AdV, adenovirus; BV, bocavirus; CoV, coronavirus; HMpV; human metapneumovirus; IFV, influenza virus; PIV, parainfluenza virus; RV/EV: rhinovirus/enterovirus.

  • a P < .05 versus RVP negative.

  • b P < .01 versus RVP negative.